

Supplementary Table 1: Locostatin inhibits a CD8⁺ T cell cytokine storm.

| Cytokine (pg/ml) | <i>No locostatin</i> | | <i>16 μM locostatin</i> | | <i>50 μM locostatin</i> | | <i>150 μM locostatin</i> | |
|------------------|----------------------|--------|-------------------------|--------|-------------------------|--------|--------------------------|--------|
| | + SIINFEKL | - | + | - | + | - | + | - |
| IL-1α | 119.26 | 31.28 | 48.04 | 26.93 | 27.48 | 31.18 | 25.36 | 32.58 |
| IL-1β | 445.74 | 7.77 | 164.27 | 58.08 | 13.76 | 6.43 | ≤5.5 | ≤5.5 |
| IL-2 | 4758.5 | 6.16 | 196.97 | 2.71 | 2.90 | ≤2 | ≤2 | ≤2 |
| IL-3 | 224.1 | 3.50 | 12.38 | 1.13 | ≤1 | ≤1 | ≤1 | ≤1 |
| IL-4 | 12.02 | 1.52 | 3.17 | 1.43 | 1.66 | 1.68 | 1.35 | 1.95 |
| IL-5 | 22.33 | 2.85 | 6.14 | ≤2.5 | ≤2.5 | ≤2.5 | ≤2.5 | ≤2.5 |
| IL-6 | 2668.45 | 346.64 | 759.02 | 265.99 | 71.29 | 24.49 | ≤2 | 2.48 |
| IL-9 | 254.50 | 122.47 | 151.02 | 80.28 | 36.81 | ≤36.5 | ≤36.5 | ≤36.5 |
| IL-10 | 219.35 | 9.72 | 188.47 | ≤5.5 | 6.67 | ≤5.5 | ≤5.5 | ≤5.5 |
| IL-12 | 64.3 | 99.37 | 29.20 | 21.85 | 16.03 | 13.83 | 10.67 | 13.29 |
| MCP-1 | 1384.96 | 691.54 | 173.21 | 78.19 | 38.34 | 26.39 | 26.65 | 35.55 |
| IFNγ | 586511.2 | 51.02 | 53217.54 | 23.38 | 79.79 | 25.93 | ≤20 | ≤20 |
| TNFα | 1859.01 | 25.32 | 413.97 | 8.59 | 110.36 | 7.13 | 9.73 | ≤5 |
| MIP-1α | 327677.05 | 207.67 | 133184.40 | 118.01 | 1803.20 | 70.55 | 98.98 | 77.20 |
| GM-CSF | 1096.33 | 9.34 | 183.80 | 2.65 | 3.24 | ≤1.5 | ≤1.5 | ≤1.5 |
| RANTES | 17105.43 | 644.10 | 15547.65 | 509.42 | 2811.63 | 862.97 | 1536.09 | 794.77 |

C57BL/6 mice adoptively transferred with 150,000 OT-I cells were immunized with OVA, poly I:C and anti-4-1BB (CD137) antibody and rested for 6 days. Spleen cells were harvested and stimulated *in vitro* with 100μg SIINFEKL peptide or vehicle in presence of increasing doses of locostatin. After 16 hours supernatants were obtained and sent to Quansys Biosciences (Logan Utah) for cytokine analysis.